Last reviewed · How we verify

NCT03634124: GT-PT

Generation of Thrombin and Prediction of Deep Vein Thrombosis Post Prosthetic Orthopedic Surgery of the Lower Limbs

Completed Phase 3 Last updated 11 February 2026
What this trial tests

Phase 3 trial testing Blood test in Deep Vein Thrombosis in 146 participants. Completed in 17 October 2023.

Timeline
21 February 2019
Primary endpoint
20 February 2023
17 October 2023

Quick facts

Lead sponsorCentre Hospitalier Universitaire de Nīmes
PhasePhase 3
StatusCompleted
Study typeINTERVENTIONAL
Allocationna
Designsingle group
Maskingnone
Primary purposeother
Enrollment146
Start date21 February 2019
Primary completion20 February 2023
Estimated completion17 October 2023
Sites1 location across France

Drugs / interventions tested

Conditions studied

Sponsor

Centre Hospitalier Universitaire de Nīmes

Who can join

18 and older, any sex, with Deep Vein Thrombosis or Total Hip Prosthesis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The numerical ratio between the value of the thrombin generation test performed without soluble thrombomodulin and the value of the thrombin generation test performed in the presence of soluble thrombomodulin, performed pre-surgically, could predict the risk of early venous thromboembolism after placement of total hip or knee prosthesis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Blood test

Trials testing the same drug.

Other recruiting trials for Deep Vein Thrombosis

Currently open trials in the same condition.

Other Centre Hospitalier Universitaire de Nīmes trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03634124.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing